Clinical Trials Browser

Phase 2 × Vorinostat × Dermatologic × Clear all

Uveal Melanoma

NCT03713320 2022-04-08

SOLAR

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00121225 2019-01-29

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Phase 2 Completed

32 enrolled 11 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT00958074 2018-10-18

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

Phase 2 Terminated

11 enrolled 11 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Phase 2 Completed

74 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02943642 2016-10-25

Resimmune®

Phase 2 Unknown

162 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00810576 2012-08-07

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Phase 2 Terminated

1 enrolled 3 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Clinical Trials

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

SOLAR

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Resimmune®

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma